Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Apex Critical Metals Corp.: Apex Critical Metals Appoints Alex Knox, P.Geo as Foundational Member of its... (Accesswire) +++ APEX CRITICAL Aktie -3,24%

AKESO Aktie

 >AKESO Aktienkurs 
15.35 EUR    (Tradegate)
Ask: 15.5 EUR / 1490 Stück
Bid: 15.2 EUR / 500 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
AKESO Aktie über LYNX handeln
>AKESO Performance
1 Woche: -3,4%
1 Monat: -7,7%
3 Monate: +81,6%
6 Monate: +90,4%
1 Jahr: +205,5%
laufendes Jahr: +131,7%
>AKESO Aktie
Name:  AKESO INC. O.N.
Land:  China
Sektor:  Gesundheit
ISIN/ Wkn:  KYG0146B1032 / A2P200
Symbol/ Ticker:  4RY (Frankfurt)
Kürzel:  FRA:4RY, ETR:4RY, 4RY:GR
Index:  -
Webseite:  https://www.akesobio.com/
Profil:  Akeso Inc. is a biopharmaceutical company focused ..
>Volltext..
Marktkapitalisierung:  15584.64 Mio. EUR
Unternehmenswert:  15269.67 Mio. EUR
Umsatz:  294.4 Mio. EUR
EBITDA:  -
Nettogewinn:  -99.09 Mio. EUR
Gewinn je Aktie:  -0.11 EUR
Schulden:  540.82 Mio. EUR
Liquide Mittel:  785.05 Mio. EUR
Operativer Cashflow:  -52.94 Mio. EUR
Bargeldquote:  3.54
Umsatzwachstum:  20.7%
Gewinnwachstum:  -3.69%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  AKESO
Letzte Datenerhebung:  08.09.25
>AKESO Kennzahlen
Aktien/ Unternehmen:
Aktien: 896.42 Mio. St.
Frei handelbar: 77.38%
Leerverk. Aktien: -
Rückkaufquote: -
Mitarbeiter: 3035
Umsatz/Mitarb.: 0.08 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 15.54%
Bewertung:
KGV: -
KGV lG: -
KUV: 48.37
KBV: -
PEG-Ratio: -18.92
EV/EBITDA: -
Rentabilität:
Bruttomarge: 84.32%
Gewinnmarge: -33.66%
Operative Marge: -28.43%
Managementeffizenz:
Gesamtkaprendite: -7.07%
Eigenkaprendite: -14.4%
>AKESO Peer Group

Es sind 101 Aktien bekannt.
 
08.09.25 - 04:36
Akeso Drops Most in 3 Months on Mixed Drug Data From US Partner (Bloomberg)
 
Akeso Inc.'s shares slumped after US partner Summit Therapeutics Inc. unveiled new data that cast doubt on the future of their closely-watched lung cancer drug in America....
02.09.25 - 10:03
Akeso Announces Completion of Patient Enrollment in Phase III Clinical Trial for Ivonescimab as First-Line Treatment for Biliary Tract Cancer Compared to PD-L1 Therapy (PR Newswire)
 
HONG KONG, Sept. 2, 2025 /PRNewswire/ -- Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized, controlled, registrational study evaluating ivonescimab, in combination with standard therapy, against durvalumab (PD-L1)......
28.08.25 - 04:45
AKESO Once Plummets 7.5% on ~5% Discounted Shr Placement & Shareholder Sell-Down (AAStocks)
 
AKESO (09926.HK) announced the entering into of a primary and a secondary placement agreement.The primary placement involves the issuance of 23.55 million new shares (around 2.56% of the enlarged issued share capital) to no fewer than six placees at a placement price of HKD149.54 per share, about a 4.75% discount to yesterday......
27.08.25 - 21:18
Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck€s Keytruda Multi-Billion Dollar Franchise, Says Analyst (Benzinga)
 
Summit and Akeso report ivonescimab's survival benefit in lung cancer, boosting approval odds and positioning it as a Keytruda challenger. Latest Ratings for SMMT DateFirmActionFromTo Nov 2020HC Wainwright & Co.DowngradesBuyNeutral Mar 2020HC Wainwright & Co.Initiates Coverage OnBuy Jun 2018Janney Montgomery ScottDowngradesBuyNeutral View More Analyst Ratings for SMMT View the Latest Analyst Ratings read more...
27.08.25 - 06:33
Akeso shares surge as cancer drug achieves key milestone in China trial (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
27.08.25 - 04:24
Akeso′s Lung Cancer Drug Hits Key Goal In China Study (Bloomberg)
 
Akeso Inc. said its closely-watched lung cancer drug has definitively demonstrated for the first time that it could help some patients live longer, potentially boosting its prospects for approval in the US....
27.08.25 - 03:45
AKESO Opens 4.7% Higher; 1H Rev. Soars ~38%, Loss Widens (AAStocks)
 
AKESO (09926.HK) opened 4.7% higher this morning (27th) at HKD177, with a pre-market trading volume of 2.2197 million shares, involving HKD381 million.The group's 1H25 revenue rose by 37.7% YoY to RMB1.412 billion, while its gross profit leaped by 18.8% to RMB1.121 billion, attributable to changes in commercial sales revenue......
26.08.25 - 17:18
Akeso′s 2025 Interim Results: Commercial Sales Reach New All-Time Highs (PR Newswire)
 
IO 2.0 + ADC 2.0 Strategy Builds a "Next-Generation" Platform with Global Competitive Edge Key Highlights: Final analysis of HARMONi-A Study: Ivonescimab met the overall survival (OS) endpoint, demonstrating a statistically significant and clinically meaningful OS benefit First......
26.08.25 - 13:03
Angeles Equity Partners and Kain Capital Appoint Peter Murray as CEO of Agile Occupational Medicine (Business Wire)
 
LOS ANGELES--(BUSINESS WIRE)--$manda #mergersandacquisitions--Angeles Equity Partners, LLC (“Angeles”), a private investment firm specializing in value creation through operational transformation, and Kain Capital LLC (“Kain”), a private equity firm focused on healthcare services and healthcare technology companies, today announced Peter Murray as CEO of Agile Occupational Medicine (“Agile”). Murray, formerly Chief Operating Officer of Agile, has been instrumental in shaping the company's strategy and operational trajectory. He successfully led the integration of six acquisitions that unified 23 clinics under one platform, and is now guiding the combination with Akeso Occupational Health. Based in California, Agile has become the nation's second-largest independent occupational medicine provider, delivering superior care to help employees recover from work-related injuries. “Peter has shown exceptional leadership and an unwavering commitment to Agile's mission since day one,” said Adam ...
25.08.25 - 07:48
Akeso Reports Phase 3 Trials Show Positive Results: Gumokimab (IL-17) for Ankylosing Spondylitis and Manfidokimab (IL-4Rα) for Atopic Dermatitis Achieve Primary Endpoints (PR Newswire)
 
HONG KONG, Aug. 25, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) ("Akeso" or "the Company") today announced positive results from its Phase 3 clinical trial of gumokimab (AK111), a novel, fully human anti-IL-17A monoclonal antibody, for the treatment of active ankylosing spondylitis (AS).......
22.08.25 - 06:15
Midday Takeaway: HSI Closes Midday at 25,184, Up 80 pts; HSTI Closes Midday at 5,586, Up 88 pts; XPENG Up over 10%; TENCENT, SINO BIOPHARM, CHOW TAI FOOK, HUA HONG SEMI, AKESO Hit New Highs (AAStocks)
 
At midday close, HSI rose 80 pts or 0.3% to 25,184. HSTI rose 88 pts or 1.6% to 5,586. HSCEI gained 47 pts or 0.5% to 9,022.Active Heavyweights:XIAOMI (01810.HK) closed at $52.35, up 1.9%TENCENT (00700.HK) closed at $601.5, up 1.4%, hitting new highBABA (09988.HK) closed at $117.2, up 1.3%MEITUAN (03690.HK) closed at $116.6, dow......
20.08.25 - 10:15
First Patient Dosed in Pivotal Phase III Trial of Cadonilimab (PD-1/CTLA-4) for Perioperative Treatment of Resectable Gastric Cancer (PR Newswire)
 
HONG KONG, Aug. 20, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the enrollment and dosing of the first patient in the pivotal Phase III clinical trial (AK104-310/COMPASSION-33) evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody......
11.08.25 - 23:09
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025 (Business Wire)
 
Ivonescimab in Combination with Chemotherapy Showed Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Global Phase III HARMONi Trial Evaluating Patients with EGFRm NSCLC after EGFR TKI Therapy; Positive Trend Observed in Overall Survival Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China; Ivonescimab Monotherapy Approved by NMPA in China for 1L PD-L1 Positive Advanced NSCLC Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant, Clinically Meaningful Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China Enrollment Continues in Summit's Global Phase III Trials HARMONi-3 in 1L NSCLC and HARMONi-7 in 1L PD-L1 High NSCLC Summit and Revolution Medicines En...
11.08.25 - 04:54
Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy (PR Newswire)
 
HONG KONG, Aug. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study (AK112-311/HARMONi-9), evaluating ivonescimab, a first-in-class PD-1/VEGF bispecific......
05.08.25 - 10:30
Full-day Takeaway: HSI Closes at 24,902, Up 169 pts; HSTI Closes at 5,521, Up 39 pts; BYD ELECTRONIC Up over 7%; XD INC, LEPU BIO, KEYMED BIO-B, AKESO, SKB BIO-B Hit New Highs; Market Turnover Rises (AAStocks)
 
At close, HSI rose 169 pts or 0.7% to 24,902. HSTI rose 39 pts or 0.7% to 5,521. HSCEI gained 57 pts or 0.6% to 8,951. Market turnover reached $229.40 billion.Active Heavyweights:TENCENT (00700.HK) closed at $559, up 1.6%CCB (00939.HK) closed at $8, up 1%PING AN (02318.HK) closed at $54.05, up 0.7%XIAOMI (01810.HK) closed at $54......
04.08.25 - 08:01
Akeso Announces Approval to Initiate Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma (PR Newswire)
 
HONG KONG, Aug. 4, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225) has been approved to initiate by both China's National Medical Products Administration (NMPA)......
31.07.25 - 03:48
Akeso Announces Completion of First Dosing in Phase III Clinical Trial of Ivonescimab (PD-1/VEGF) Combination Therapy for Immunotherapy-Resistant NSCLC (PR Newswire)
 
HONG KONG, July 30, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its pivotal Phase III clinical study (AK112-305/HARMONi-8A) of ivonescimab (PD-1/VEGF bispecific antibody) in combination with docetaxel for the......
28.07.25 - 06:18
NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer (PR Newswire)
 
HONG KONG, July 28, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration (NMPA) has accepted the supplementary New Drug Application (sNDA) for ivonescimab (PD-1/VEGF bispecific antibody) in......
24.07.25 - 03:18
Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer (PR Newswire)
 
HONG KONG, July 23, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been enrolled in the pivotal/registration Phase III clinical trial (AK112-310/HARMONi-GI2) of ivonescimab, a first-in-class PD-1/VEGF bispecific......
18.07.25 - 06:00
Research: JPM Favors AKESO/ INNOVENT BIO/ HENGRUI PHARMA as CN Healthcare Sector Rebounds Sharply This Yr (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Mittelmaß . . . Die übliche Ballungszone des menschlichen Geistes. - Julio Cortázar
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!